11/10/2025
77/2025 (1370)
💡DUPILUMAB COMBINED WITH SUBCUTANEOUS IMMUNOTHERAPY IN HOUSE DUST MITE–SENSITIZED ATOPIC DERMATITIS: Patients with atopic dermatitis (AD) are frequently sensitized to house dust mites (HDM). Although Dupilumab is effective, the role of subcutaneous immunotherapy (SCIT) in this population remains unclear. The investigators evaluated the safety and clinical outcomes of combining Dupilumab with HDM-SCIT in 47 adults with HDM-sensitised AD who received both treatments concurrently for 48 weeks. Eczema Area and Severity Index (EASI) scores as well as total and HDM-specific IgE levels were assessed. Safety was monitored by adverse events related to SCIT and Dupilumab. EASI scores improved markedly from baseline (28.4 ± 6.9) to week 12 (14.8 ± 4.5), week 24 (12.7 ± 4.3), and week 48 (5.2 ± 2.8). HDM-specific IgE and total IgE decreased significantly by week 48 (p < 0.05). SCIT-related local and systemic reactions diminished over time. Dupilumab-associated conjunctivitis, head and neck dermatitis, and upper respiratory infections were transient and resolved during follow-up. The combination of Dupilumab and SCIT was well tolerated and associated with sustained clinical improvement and IgE reduction in HDM-sensitised AD patients. These results support further investigation in prospective controlled trials.
Source:
Clin Exp Allergy. 2025 May 7. doi: 10.1111/cea.70077.
Exploratory Safety Evaluation of Dupilumab Combined With Subcutaneous Immunotherapy in House Dust Mite-Sensitised Patients With Atopic Dermatitis.
Li X, Li Y, Zhang J, Wu S, Ai L, Tong X, Fan C, Cai H, Guo J, Gao T, Liu P, Liu N, Jin P, Zhi L.